Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 114868
1. Paydar I, Pepin A, Cyr RA, King J, Yung TM, Bullock EG, Lei S, Satinsky A, Harter KW, Suy S, Dritschilo A, Lynch JH, Kole TP, Collins SP: Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity. Front Oncol; 2017;7:5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.
  • BACKGROUND: Recent data suggest that intensity-modulated radiation therapy (IMRT) plus brachytherapy boost for unfavorable prostate cancer provides improved biochemical relapse-free survival over IMRT alone.
  • MATERIALS AND METHODS: Between March 2008 and September 2012, patients with prostate cancer were treated with robotic SBRT (19.5 Gy in three fractions) followed by fiducial-guided IMRT (45-50.4 Gy) on an institutional protocol.
  • Toxicity was prospectively graded using the common terminology criteria for adverse events version 4.0 (CTCAEv.4) at the start of and at 1- to 6-month intervals after therapy.
  • Future studies should compare cancer control, quality of life, and toxicity with other treatment modalities for patients with high-risk prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Technol Cancer Res Treat. 2010 Oct;9(5):453-62 [20815416.001]
  • [Cites] Front Oncol. 2016 May 06;6:114 [27200300.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):150-4 [16111583.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):937-9 [26530768.001]
  • [Cites] Radiother Oncol. 1998 Mar;46(3):285-95 [9572622.001]
  • [Cites] J Urol. 2015 Dec;194(6):1624-30 [26165583.001]
  • [Cites] Radiat Oncol. 2016 Jan 21;11:8 [26792201.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):125-9 [22330997.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):751-8 [20207506.001]
  • [Cites] Technol Cancer Res Treat. 2010 Dec;9(6):575-82 [21070079.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1192-9 [15718316.001]
  • [Cites] Radiother Oncol. 2012 Jul;104(1):114-8 [22727264.001]
  • [Cites] Radiat Oncol. 2013 Mar 13;8:58 [23497695.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1048-55 [15001244.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):1990-6 [16648499.001]
  • [Cites] Urology. 2000 Dec 20;56(6):899-905 [11113727.001]
  • [Cites] Acta Oncol. 2005;44(3):265-76 [16076699.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):316-27 [12023135.001]
  • [Cites] Cancer. 2015 Jul 15;121(14):2422-30 [25847819.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):999-1007 [16750320.001]
  • [Cites] Urology. 2000 Mar;55(3):382-6 [10699615.001]
  • [Cites] Radiat Oncol. 2013 Jan 31;8:30 [23369294.001]
  • [Cites] Radiother Oncol. 2012 May;103(2):217-22 [22341794.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):877-82 [21300474.001]
  • [Cites] Cancer. 2013 Feb 1;119(3):681-90 [22893254.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):383-7 [18947938.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):67-74 [17765406.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2630-7 [10375112.001]
  • [Cites] J Urol. 2016 Jun;195(6):1811-6 [26778712.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):679-85 [22954770.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1443-53 [27325475.001]
  • [Cites] Radiother Oncol. 2000 Jan;54(1):11-9 [10719695.001]
  • [Cites] Radiat Oncol. 2014 Jan 01;9:1 [24382205.001]
  • [Cites] Br J Radiol. 2015 Oct;88(1054):20140736 [26235142.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Aug 1;92 (5):971-7 [26054865.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):932-8 [24113055.001]
  • [Cites] Front Oncol. 2014 Oct 31;4:278 [25401085.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 2):S21-5; discussion S26-7 [14610406.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):646-55 [17531401.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1306-16 [15817332.001]
  • [Cites] Radiat Oncol. 2014 Dec 12;9:277 [25497602.001]
  • [Cites] Radiother Oncol. 2009 May;91(2):232-6 [19097660.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5366-73 [18048817.001]
  • [Cites] JAMA. 2005 Sep 14;294(10):1233-9 [16160131.001]
  • [Cites] Front Oncol. 2015 Sep 01;5:194 [26389077.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):184-91 [12694837.001]
  • [Cites] J Urol. 2007 Jan;177(1):123-7; discussion 127 [17162020.001]
  • (PMID = 28224113.001).
  • [Journal-full-title] Frontiers in oncology
  • [ISO-abbreviation] Front Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; CyberKnife / IMRT / SBRT / common terminology criteria / prostate cancer
  •  go-up   go-down


2. Williams F, Imm KR, Colditz GA, Housten AJ, Yang L, Gilbert KL, Drake BF: Physician role in physical activity for African-American males undergoing radical prostatectomy for prostate cancer. Support Care Cancer; 2017 Apr;25(4):1151-1158

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physician role in physical activity for African-American males undergoing radical prostatectomy for prostate cancer.
  • PURPOSE: Physical activity is recognized as a complementary therapy to improve physical and physiological functions among prostate cancer survivors.
  • Little is known about communication between health providers and African-American prostate cancer patients, a high risk population, regarding the health benefits of regular physical activity on their prognosis and recovery.
  • This study explores African-American prostate cancer survivors' experiences with physical activity prescription from their physicians.
  • METHODS: Three focus group interviews were conducted with 12 African-American prostate cancer survivors in May 2014 in St. Louis, MO.
  • These findings highlight the importance of physical activity communication and prescription for prostate cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27999951.001).
  • [ISSN] 1433-7339
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; African-American / Physical activity / Physician / Prescription/communication / Prostate cancer / Survivor
  •  go-up   go-down


3. Javanmard B, Hassanzadeh Haddad A, Yaghoobi M, Lotfi B: Diode laser ablation of prostate and channel transurethral resection of prostate in patients with prostate cancer and bladder outlet obstruction symptoms. Urol J; 2014 Jul-Aug;11(4):1788-92
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diode laser ablation of prostate and channel transurethral resection of prostate in patients with prostate cancer and bladder outlet obstruction symptoms.
  • PURPOSE: To evaluate the efficacy of diode laser ablation of prostate for treating lower urinary tract symptoms (LUTS) in patients with locally advanced prostate cancer and comparing results with palli­ative transurethral resection of prostate (pTURP).
  • MATERIALS AND METHODS: Thirty-six known cases of locally advanced prostate cancer with a maximum urinary flow rate (Qmax) of 12 mL per second or less and an International Prostate Symptom Score (IPSS) of 20 or more were included in this study.
  • The first group underwent pTURP and for the second group diode laser ablation of prostate was done.
  • CONCLUSION: Diode laser ablation of prostate and pTURP, both improved significantly IPSS, PVR and Qmax.
  • [MeSH-major] Ablation Techniques / instrumentation. Carcinoma / surgery. Lasers, Semiconductor / therapeutic use. Palliative Care. Prostatic Neoplasms / surgery. Prostatism / surgery. Urinary Bladder Neck Obstruction / surgery
  • [MeSH-minor] Aged. Humans. Length of Stay. Male. Middle Aged. Operative Time. Time Factors. Transurethral Resection of Prostate. Urinary Catheterization. Urodynamics

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25194077.001).
  • [ISSN] 1735-546X
  • [Journal-full-title] Urology journal
  • [ISO-abbreviation] Urol J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Iran
  •  go-up   go-down


Advertisement
4. Giannarini G, Crestani A, Rossanese M, Ficarra V: Multiparametric Magnetic Resonance Imaging Targeted Biopsy for Early Detection of Prostate Cancer: All That Glitters Is Not Gold! Eur Urol; 2017 Jun;71(6):904-906

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiparametric Magnetic Resonance Imaging Targeted Biopsy for Early Detection of Prostate Cancer: All That Glitters Is Not Gold!

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28094057.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] Switzerland
  •  go-up   go-down


5. Li J, Hall IJ, Zhao G: Prostate cancer screening decision-making in three states: 2013 behavioral risk factor surveillance system analysis. Cancer Causes Control; 2017 Mar;28(3):235-240
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer screening decision-making in three states: 2013 behavioral risk factor surveillance system analysis.
  • INTRODUCTION: Given the discordant prostate cancer screening recommendations in the United States, shared decision-making (SDM) has become increasingly important.
  • The objectives of this study were to determine who made the final decision to obtain prostate-specific antigen (PSA)-based screening and identify factors associated with the screening decision made by both patients and their health care providers.
  • Only 36% of them made their prostate cancer screening decision jointly with their health care provider.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28210882.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Prostate cancer screening / Prostate-specific antigen test / Shared decision-making
  •  go-up   go-down


6. Nam RK, Zhang WW, Trachtenberg J, Seth A, Klotz LH, Stanimirovic A, Punnen S, Venkateswaran V, Toi A, Loblaw DA, Sugar L, Siminovitch KA, Narod SA: Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res; 2009 Mar 1;15(5):1787-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of incorporating genetic variants for the early detection of prostate cancer.
  • PURPOSE: Several single nucleotide polymorphisms (SNP) have been associated with the risk of prostate cancer.
  • The clinical utility of using SNPs in the early detection of prostate cancer has not been evaluated.
  • EXPERIMENTAL DESIGN: We examined a panel of 25 SNPs from candidate genes and chromosomal regions in 3,004 unselected men who were screened for prostate cancer using serum prostate-specific antigen (PSA) and digital rectal examination.
  • All underwent a prostate biopsy.
  • We evaluated the ability of these SNPs to help predict the presence of prostate cancer at biopsy.
  • RESULTS: Of the 3,004 patients, 1,389 (46.2%) were found to have prostate cancer.
  • Fifteen of the 25 SNPs studied were significantly associated with prostate cancer (P=0.02-7x10(-8)).
  • CONCLUSIONS: SNP genotyping can be used in a clinical setting for the early detection of prostate cancer in a nomogram approach and by improving the positive predictive value of the PSA test.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Genetic Markers / genetics. Polymorphism, Single Nucleotide / genetics. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Area Under Curve. Biopsy. Case-Control Studies. Early Diagnosis. Genotype. Humans. Male. Middle Aged. Models, Genetic. Odds Ratio. Polymerase Chain Reaction. Prognosis. Prostate-Specific Antigen / blood. ROC Curve. Risk Factors

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223501.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / PHS HHS / / 010294
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


7. Jeong HJ, Kwon DD: Continence rate and oncological feasibility after total transurethral resection of the prostate as an alternative therapy for the treatment of prostate cancer: a pilot study. Int Neurourol J; 2011 Dec;15(4):222-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continence rate and oncological feasibility after total transurethral resection of the prostate as an alternative therapy for the treatment of prostate cancer: a pilot study.
  • PURPOSE: The value of total transurethral resection of prostate cancer (TURPC) as an alternative therapy was first recognized by Hans J. Reuter.
  • Thus, we conducted the study of prospectively collected data to verify total TURPC as an alternative therapy forlocalized prostate cancer.
  • METHODS: From January 2008 to July 2011, 14 patients with a mean age of 76.1 years (range, 66 to 89 years) with clinically localized prostate cancer were treated by prostatic resection by the corresponding author with curative intention.
  • RESULTS: The mean duration of TURPC was 51.7 minutes (range, 30 to 120 minutes) and the mean amount of prostatic tissue resected was 21.2 g (range, 5 to 66 g).
  • Three patients in the high-risk group did not achieve a prostate specific antigen (PSA) nadir of ≤0.2 ng/mL.
  • CONCLUSIONS: According to our results, transurethral resection for prostate cancer can be performed with reasonable oncological results.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22259737.001).
  • [ISSN] 2093-6931
  • [Journal-full-title] International neurourology journal
  • [ISO-abbreviation] Int Neurourol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3256308
  • [Keywords] NOTNLM ; Prostate-specific antigen / Prostatic neoplasms / Transurethral resection of prostate / Urinary incontinence
  •  go-up   go-down


8. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med; 1999 Dec 9;341(24):1781-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.
  • BACKGROUND: Because the optimal timing of the institution of antiandrogen therapy for prostate cancer is controversial, we compared immediate and delayed treatment in patients who had minimal residual disease after radical prostatectomy.
  • METHODS: Ninety-eight men who underwent radical prostatectomy and pelvic lymphadenectomy and who were found to have nodal metastases were randomly assigned to receive immediate antiandrogen therapy, with either goserelin, a synthetic agonist of gonadotropin-releasing hormone, or bilateral orchiectomy, or to be followed until disease progression.
  • The cause of death was prostate cancer in 3 men in the immediate-treatment group and in 16 men in the observation group (P<0.01).
  • At the time of the last follow-up, 36 men in the immediate-treatment group (77 percent) and 9 men in the observation group (18 percent) were alive and had no evidence of recurrent disease, including undetectable serum prostate-specific antigen levels (P<0.001).
  • In the observation group, the disease recurred in 42 men; 13 of the 36 who were treated had a complete response to local treatment or hormonal therapy (or both), 16 died of prostate cancer, and 1 died of another disease.
  • The remaining men in this group were alive with progressive disease at the time of the last follow-up or had had a recent relapse.
  • CONCLUSIONS: Immediate antiandrogen therapy after radical prostatectomy and pelvic lymphadenectomy improves survival and reduces the risk of recurrence in patients with node-positive prostate cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Goserelin / therapeutic use. Orchiectomy. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / surgery
  • [MeSH-minor] Aged. Combined Modality Therapy. Disease Progression. Follow-Up Studies. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Prostatectomy. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GOSERELIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] N Engl J Med. 2000 Apr 20;342(16):1215-6 [10777375.001]
  • [CommentIn] N Engl J Med. 1999 Dec 9;341(24):1837-8 [10588970.001]
  • (PMID = 10588962.001).
  • [ISSN] 0028-4793
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA23318; etc
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0F65R8P09N / Goserelin
  •  go-up   go-down


9. Alibhai SMH, Zukotynski K, Walker-Dilks C, Emmenegger U, Finelli A, Morgan SC, Hotte SJ, Winquist E, Cancer Care Ontario Genitourinary Cancer Disease Site Group: Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline. Clin Oncol (R Coll Radiol); 2017 Jun;29(6):348-355

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
  • AIMS: To make recommendations with respect to bone health and bone-targeted therapies in men with prostate cancer.
  • Systematic reviews and randomised-controlled trials were considered for inclusion if they involved therapies directed at improving bone health or outcomes such as skeletal-related events, pain and quality of life in patients with prostate cancer either with or without metastases to bone.
  • Disease-targeted agents such as androgen receptor-targeted and chemotherapeutic agents were excluded.
  • RESULTS: In men with prostate cancer receiving androgen deprivation therapy, baseline bone mineral density testing is encouraged.
  • Denosumab and zoledronic acid are recommended for preventing or delaying skeletal-related events in men with metastatic castration-resistant prostate cancer.
  • Radium-223 is recommended for reducing symptomatic skeletal events and prolonging survival in men with symptomatic metastatic castration-resistant prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 28169118.001).
  • [ISSN] 1433-2981
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Bone mineral density / bone-targeted therapy / denosumab / prostate cancer / radium-223 / zoledronic acid
  •  go-up   go-down


10. Fu AZ, Tsai HT, Haque R, Yood MU, Cassidy-Bushrow AE, Van Den Eeden SK, Keating NL, Smith MR, Zhou Y, Aaronson DS, Potosky AL: Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer. J Urol; 2017 Jun;197(6):1448-1454
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
  • PURPOSE: Androgen deprivation therapy is often used as salvage treatment in men with rising prostate specific antigen after initial radical prostatectomy or radiotherapy for clinically localized prostate cancer.
  • MATERIALS AND METHODS: From 3 managed care organizations we assembled a retrospective cohort of all 5,804 men with newly diagnosed localized prostate cancer from 1995 to 2009 who had a prostate specific antigen increase (biochemical recurrence) after primary radical prostatectomy or radiotherapy.
  • The main outcomes were all-cause and prostate cancer specific mortality.
  • RESULTS: Overall salvage androgen deprivation therapy was not associated with all-cause or prostate cancer specific mortality in the prostatectomy cohort (HR 0.97, 95% CI 0.70-1.35 or HR 1.18, 95% CI 0.68-2.07) or in the radiotherapy cohort (HR 0.84, 95% CI 0.70-1.01 or HR 1.06, 95% CI 0.80-1.40, respectively).
  • Among men with prostate specific antigen doubling time less than 9 months after the prostate specific antigen rise, salvage androgen deprivation therapy was statistically significantly associated with a decreased risk of all-cause and prostate cancer specific mortality in the prostatectomy cohort (HR 0.35, 95% CI 0.20-0.63 and HR 0.43, 95% CI 0.21-0.91) and in the radiotherapy cohort (HR 0.62, 95% CI 0.48-0.80 and HR 0.65, 95% CI 0.47-0.90, respectively).
  • CONCLUSIONS: We found no association of salvage androgen deprivation therapy with all-cause or cause specific mortality in most men with biochemical recurrence after primary radical prostatectomy or radiotherapy for clinically localized prostate cancer.
  • Men with quickly progressed disease may derive a clinical benefit from salvage androgen deprivation therapy.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
  • [Cites] JAMA. 2005 Jul 27;294(4):433-9 [16046649.001]
  • [Cites] Lancet Oncol. 2016 Jun;17(6):727-37 [27155740.001]
  • [Cites] Prog Urol. 2013 Feb;23(2):88-95 [23352300.001]
  • [Cites] Cancer. 2008 Jan 15;112(2):307-14 [18050294.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1227-32 [21549519.001]
  • [Cites] J Clin Oncol. 2014 May 1;32(13):1324-30 [24638009.001]
  • [Cites] J Urol. 2004 Mar;171(3):1141-7 [14767288.001]
  • [Cites] J Urol. 2002 May;167(5):1952-6 [11956415.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3750-7 [11533098.001]
  • [Cites] Eur Urol. 2016 May;69(5):802-20 [26691493.001]
  • [Cites] Med Care. 1998 Jan;36(1):8-27 [9431328.001]
  • [Cites] Am J Manag Care. 2014 Dec;20(12 Suppl):S273-81 [25734963.001]
  • [Cites] World J Urol. 2016 Dec;34(12 ):1611-1619 [27084777.001]
  • [Cites] Hematol Oncol Clin North Am. 2013 Dec;27(6):1205-19, viii [24188259.001]
  • [Cites] Osteoporos Int. 2005 Jun;16(6):707-11 [15714259.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74 [16798415.001]
  • [Cites] CA Cancer J Clin. 2010 May-Jun;60(3):194-201 [20124400.001]
  • [Cites] N Engl J Med. 2012 Sep 6;367(10):895-903 [22931259.001]
  • [Cites] J Gen Intern Med. 2013 Nov;28(11):1440-6 [23670565.001]
  • [Cites] J Natl Compr Canc Netw. 2004 May;2(3):249-56 [19795608.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4448-56 [16983113.001]
  • [Cites] Clin Adv Hematol Oncol. 2012 Nov;10(11):716-22 [23271258.001]
  • [Cites] Eur Urol. 2007 Mar;51(3):605-13; discussion 613 [17113217.001]
  • [Cites] BJU Int. 2012 Jan;109(1):32-9 [21777360.001]
  • [Cites] Anticancer Res. 2010 May;30(5):1633-6 [20592353.001]
  • [Cites] J Urol. 2008 May;179(5):1830-7; discussion 1837 [18353378.001]
  • (PMID = 28007467.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA051008; United States / NCI NIH HHS / CA / R01 CA142934; United States / NCI NIH HHS / CA / RC1 CA146238
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; androgen antagonists / local / mortality / neoplasm recurrence / prostatic neoplasms / salvage therapy
  •  go-up   go-down






Advertisement